Disclosures: ST, FM, GZ, and SJ received funding from Grifols to attend scientific meetings. The Institution of ST and FM received money from Pfizer for educational activities on neuropathic pain and received the EFIC Grünenthal Grant 2010. KB received grants from Grifols, the Stockholm County (ALF), and the Karolinska Institutet, Sverige. XJC, LW, and PJS have no relevant financial interests or conflicts related to this manuscript. SJ received support for travel from Kedrion and received unconditioned grant support from Grifols to conduct clinical studies. SJ served as speaker for CLS-Behring. AJC received funding from the Bayer/Talecris/Canadian Blood Services/Héma-Québec Partnership Fund, Canada. GS serves on scientific advisory boards for Kanae Science Foundation for the Promotion of Medical Science, Naito Science Foundation, and is funded by the Ministry of Education, Culture, Sports, Science, and Technology of Japan; the Ministry of Welfare, Health, and Labor of Japan; and the Japan Science and Technology Agency, Core Research for Evolutional Science and Technology. HK received research support from the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, a grant from the Ministry of Health, Welfare, and Labor of Japan, and the Kimi Imai Memorial Foundation for Research of Incurable Neuromuscular Diseases. AV and the University of Oxford hold patents and receive royalties and payments for antibody assays. AG received research support, travel support, speaker honoraria, and consultancy fees from Axsone, CSL-Behring, BPL, Biotest, Talecris, Baxter, Grifols, and Pfizer.
Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop
Article first published online: 14 JAN 2014
Wiley Periodicals, Inc
Volume 15, Issue 7, pages 1072–1082, July 2014
How to Cite
Tamburin, S., Borg, K., Caro, X. J., Jann, S., Clark, A. J., Magrinelli, F., Sobue, G., Werhagen, L., Zanette, G., Koike, H., Späth, P. J., Vincent, A. and Goebel, A. (2014), Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 15: 1072–1082. doi: 10.1111/pme.12319
Funding: The Expert Workshop (Liverpool, UK, October 2012), upon which the present manuscript was based, was supported by The Pain Relief Foundation, Liverpool The Great-Britain Sasakawa Foundation Awards Programme; Baxter; BPL; Biotest; CSL-Behring; and Grifols.
Contributorship Statement: ST and AG designed the article, collected and interpreted the data, and drafted and revised the manuscript. KB, XJC, SJ, AJC, HK, PJS, and AV collected and interpreted the data, drafted parts of the manuscript, and revised it for important intellectual content. FM, GS, LW, and GZ collected and interpreted the data and revised the manuscript for important intellectual content. All authors approved the final version of the article. ST and AG take full responsibility for the content of this article.
- Issue published online: 24 JUL 2014
- Article first published online: 14 JAN 2014
- The Pain Relief Foundation
- Liverpool The Great-Britain Sasakawa Foundation Awards Programme
This article has been cited by:
- 1Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome): a multicenter, double-blind trial, Journal of Neurology, 2015, 262, 3, 752, , , ,
- 2Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome, Nature Reviews Rheumatology, 2015, 11, 11, 639,
- You have free access to this content3
- You have free access to this content4